Erratum: Integrated genomic analyses of ovarian carcinoma (Nature (2011) 474 (609-615) DOI: 10.1038/nature10166);Integrated genomic analyses of ovarian carcinoma

Nature

Volumn 474, Issue 7353, 2011, Pages 609-615

  Bell, D ^a   Berchuck, A ^b   Birrer, M ^c,d   Chien, J ^a   Cramer, D W ^e   Dao, F ^f   Dhir, R ^g   Disaia, P ^h   Gabra, H ⁱ   Glenn, P ^j   Godwin, A K ^k   Gross, J ^l   Hartmann, L ^a   Huang, M ^k   Huntsman, D G ^m   Iacocca, M ⁿ   Imielinski, M ^d   Kalloger, S ^m   Karlan, B Y ^l,o   Levine, D A ^f,q,u   Mills, G B ^a,p   Morrison, C ^q   Mutch, D ^r   Olvera, N ^f   Orsulic, S ^l   Park, K ^f   Petrelli, N ^s   Rabeno, B ⁿ   Rader, J S ^t   Sikic, B I ^u   Smith Mccune, K ^j   Sood, A K ^p   Bowtell, D ^v   Penny, R ^q,w   Testa, J R ^k   Chang, K ^b   Dinh, H H ^x   Drummond, J A ^c   Fowler, G ^c   Gunaratne, P ^d   Hawes, A C ^e   Kovar, C L ^b   Lewis, L R ^a   Morgan, M B ^a   Newsham, I F ^f   Santibanez, J ^e   Reid, J G ^e   Trevino, L R ^f   Wu, Y Q ^ak   Wang, M ^aa   Muzny, D M ^x   Wheeler, D A ^y   Gibbs, R A ^z   Getz, G ^f,u   Lawrence, M S ^f,x   Cibulskis, K ^x,z   Sivachenko, A Y ^z   Sougnez, C ^u   Voet, D ^u,y   Wilkinson, J ^y   Bloom, T ^z   Ardlie, K ^z,aw   Fennell, T ^b   Baldwin, J ^c   Gabriel, S ^f   Lander, E S ^r   Ding, L ^u   Fulton, R S ^aa   Koboldt, D C ^ab   McLellan, M D ^aj   Wylie, T ^ac   Walker, J ^ac   O'Laughlin, M ^aa   Dooling, D J ^ac   Fulton, L ^c   Abbott, R ^d   Dees, N D ^ad   Zhang, Q ^ae   Kandoth, C ^af   Wendl, M ^e   Schierding, W ^an   Shen, D ^an   Harris, C C ^d   Schmidt, H ^c   Kalicki, J ^ag   Delehaunty, K D ^u   Fronick, C C ^u   Demeter, R ^ah   Cook, L ^ai   Wallis, J W ^c   Lin, L ^aj   Magrini, V J ^aj   Hodges, J S ^ak   Eldred, J M ^al   Smith, S M ^am   Pohl, C S ^an   Vandin, F ^ao   Raphael, B J ^f   Weinstock, G M ^f   Mardis, E R ^f   Wilson, R K ^f   Meyerson, M ^an   Winckler, W ^f   Verhaak, R G W ^ap   Carter, S L ^ap   Mermel, C H ^aa   Saksena, G ^u,aq   Nguyen, H ^aq   Onofrio, R C ^ar   Hubbard, D ^as   Gupta, S ^at   Crenshaw, A ^au   Ramos, A H ^av   Chin, L ^u,ax   Protopopov, A ^p   Zhang, Juinhua ^p   Kim, T M ^ay   Perna, I ^az   Xiao, Y ^ba   Zhang, H ^f,bb   Ren, G ^bc   Sathiamoorthy, N ^a   Park, R W ^b,f   Lee, E ^b   Park, P J ^c,f   Kucherlapati, R ^c   Absher, D M ^a   Waite, L ^c   Sherlock, G ^d   Brooks, J D ^a   Li, J Z ^e   Xu, J ^e   Myers, R M ^b   Laird, P W ^q   Cope, L ^ab   Herman, J G ^f   Shen, H ^r   Weisenberger, D J ^x   Noushmehr, H ^r   Pan, F ^x   Triche Jr, T ^y   Berman, B P ^y   Van Den Berg, D J ^ao   Buckley, J ^f   Baylin, S B ^at   Spellman, P T ^u,aa   Purdom, E ^u   Neuvial, P ^f,an   Bengtsson, H ^f,ab   Jakkula, L R ^ah   Durinck, S ^d,u   Han, J ^a,f   Dorton, S ^f   Marr, H ^f   Choi, Y G ^at   Wang, V ^an   Wang, N J ^ac   Ngai, J ^u   Conboy, J G ^aa   Parvin, B ^aa   Feiler, H S ^r   Speed, T P ^d,u   Gray, J W ^c,aa   Socci, N D ^k   Liang, Y ^c   Taylor, B S ^d   Schultz, N ^a,aa   Borsu, L ^d,e   Lash, A E ^f   Brennan, C ^av   Viale, A ^u   Sander, C ^u   Ladanyi, M ^e,f   Hoadley, K A ^y,at   Meng, S ^ba   Du, Y ^d,bc   Shi, Y ^f   Li, L ^u   Turman, Y J ^aa   Zang, D ^aa   Helms, E B ^d   Balu, S ^d,e   Zhou, X ^a   Wu, J ^e   Topal, M D ^g   Hayes, D N ^b,f   Perou, C M ^a   Wu, C J ^x   Shukla, S ^x   Sivachenko, A ^u   Jing, R ^f   Liu, Y ^ba   Noble, M ^ao   Carter, H ^aa   Kim, D ^aa   Karchin, R ^f   Korkola, J E ^an   Heiser, L M ^e   Cho, R J ^aj   Hu, Z ^u   Cerami, E ^c   Olshen, A ^a   Reva, B ^a   Antipin, Y ^d   Shen, R ^d   Mankoo, P ^c   Sheridan, R ^c   Ciriello, G ^ab   Chang, W K ^x   Bernanke, J A ^aa   Haussler, D ^z   Benz, C C ^c   Stuart, J M ^a   Benz, S C ^d   Sanborn, J Z ^c   Vaske, C J ^c   Zhu, J ^d   Szeto, C ^c   Scott, G K ^d   Yau, C ^c   Wilkerson, M D ^y   Zhang, N ^r   Akbani, R ^b   Baggerly, K A ^d   Yung, W K ^c   Weinstein, J N ^e   Shelton, T ^c   Grimm, D ^d   Hatfield, M ^a   Morris, S ^an   Yena, P ^d   Rhodes, P ^d   Sherman, M ^a   Paulauskis, J ^a   Millis, S ^d   Kahn, A ^d   Greene, J M ^d   Sfeir, R ^d   Jensen, M A ^a   Chen, J ^d   Whitmore, J ^f   Alonso, S ^d   Jordan, J ^a   Chu, A ^a   Barker, A ^u   Compton, C ^af   Eley, G ^bc   Ferguson, M ^f   Fielding, P ^ba   Gerhard, D S ^ba   Myles, R ^ba   Schaefer, C ^ba   Mills Shaw, K R ^ba   Vaught, J ^ba   Vockley, J B ^ba   Good, P J ^bc   Guyer, M S ^bc   Ozenberger, B ^bc   Peterson, J ^bc   Thomson, E ^bc   more..

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ CHRISTIANA CARE HEALTH SYSTEM   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q ROSWELL PARK CANCER INSTITUTE   (United States)

^r WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s HELEN F GRAHAM CANCER CENTER   (United States)

^t MEDICAL COLLEGE OF WISCONSIN   (United States)

^u STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v PETER MACCALLUM CANCER CENTRE   (Australia)

^w International Genomics Consortium   (United States)

^x BAYLOR COLLEGE OF MEDICINE   (United States)

^y HARVARD UNIVERSITY   (United States)

^z MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^aa Brown Univerity   (United States)

^ab USA   (United States)

^ac DANA FARBER CANCER INSTITUTE   (United States)

^ad Harvard Medical School Center for Biomedical Informatics   (United States)

^ae LABORATORY FOR MOLECULAR MEDICINE   (United States)

^af BOSTON CHILDREN S HOSPITAL   (United States)

^ag HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY   (United States)

^ah UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^ai UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^aj JOHNS HOPKINS UNIVERSITY   (United States)

^ak LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^al UNIVERSITY OF CALIFORNIA   (United States)

^am University of California Berkeley   (United States)

^an University of Houston   (United States)

^ao WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^ap UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^aq UNIVERSITY OF NORTH CAROLINA   (United States)

^ar Johns Hopkins University   (United States)

^as Weill Cornell Graduate School of Biomedical Sciences   (United States)

^at WEILL CORNELL MEDICAL COLLEGE   (United States)

^au University of California Santa Cruz   (United States)

^av UNIVERSITY OF CALIFORNIA   (United States)

^aw BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^ax PRINCETON UNIVERSITY   (United States)

^ay SRA Int   (United States)

^az ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^ba NATIONAL CANCER INSTITUTE   (United States)

^bb MLF Consulting   (United States)

^bc NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CSMD3 PROTEIN; CYCLIN DEPENDENT KINASE 12 PROTEIN; EINSTEINIUM; FAT 3 PROTEIN; GAMMA AMINOBUTYRIC ACID RECEPTOR RECEPTOR 6; MICRORNA; NUCLEAR FACTOR I; PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR FOXM1 PROTEIN; UNCLASSIFIED DRUG;

CANCER; DISEASE TREATMENT; GENE EXPRESSION; GENETIC ANALYSIS; GENOMICS; MITOCHONDRIAL DNA; MOLECULAR ANALYSIS; MUTATION; PATHOGEN; PHYSIOLOGY; RECOMBINATION; REPRODUCTIVE HEALTH; TUMOR;

ARTICLE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOME; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

EID: 79959838081     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11453     Document Type: Erratum

References (51)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Koonings, P. P., Campbell, K., Mishell, D. R. Jr & Grimes, D. A. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet. Gynecol. 74, 921-926 (1989). (Pubitemid 20003288)
3. Seidman, J. D. et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23, 41-44 (2004). (Pubitemid 38018236)
4. Miller, D. S. et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol. 27, 2686-2691 (2009).
5. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
6. Pal, T. et al. BRCA1 and BRCA2mutations account for a large proportion of ovarian carcinoma cases. Cancer 104, 2807-2816 (2005). (Pubitemid 41798292)
7. Risch, H. A. et al. Population BRCA1 and BRCA2mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst. 98, 1694-1706 (2006). (Pubitemid 44942707)
8. Bast, R. C. Jr, Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nature Rev. Cancer 9, 415-428 (2009).
9. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nature Biotechnol. 27, 182-189 (2009).
10. Hodges, E. et al. Hybrid selection of discrete genomic intervals on customdesigned microarrays for massively parallel sequencing. Nature Protocols 4, 960-974 (2009).
11. Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27, 1419-1425 (2009).
12. Muggia, F. M. et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18, 106-115 (2000). (Pubitemid 30036343)
13. Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49-56 (2010).
14. Chen, H. H., Wang, Y. C. & Fann, M. J. Identification and characterization of the CDK12/cyclinL1 complex involved in alternative splicing regulation. Mol. Cell. Biol. 26, 2736-2745 (2006).
15. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
16. Aldred, M. A. & Trembath, R. C. Activating and inactivatingmutations in the human GNAS1 gene. Hum. Mutat. 16, 183-189 (2000).
17. Forbes, S. A. et al. in Current Protocols inHuman Genetics (eds Haines, J. L. et al. ) Ch. 10, Unit 10. 11 (Wiley, 2008).
18. McKusick, V. A. Mendelian Inheritance in Man and its online version, OMIM. Am. J. Hum. Genet. 80, 588-604 (2007). (Pubitemid 46564398)
19. Carter, H. et al. Cancer-specific high-throughput annotation of somaticmutations: computational prediction of driver missense mutations. Cancer Res. 69, 6660-6667 (2009).
20. Carter, H., Samayoa, J., Hruban, R. H. & Karchin, R. Prioritization of drivermutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol. Ther. 10, 582-587 (2010).
21. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
22. Etemadmoghadam, D. et al. Integrated genome-wide DNA copy number and expression analysis identifies distinctmechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 15, 1417-1427 (2009).
23. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007).
24. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
25. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198-5208 (2008).
26. Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9, 1191-1197 (2008).
27. Cheng, K. W. et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature Med. 10, 1251-1256 (2004). (Pubitemid 39540444)
28. Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564-569 (2000). (Pubitemid 30212318)
29. Bonome, T. et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68, 5478-5486 (2008).
30. Dressman, H. K. et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517-525 (2007). (Pubitemid 350002958)
31. Creighton, C. J. et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol. 26, 4078-4085 (2008).
32. Keshava Prasad, T. S. et al. Human Protein Reference Database-2009 update. Nucleic Acids Res. 37, D767-D772 (2009).
33. Vandin, F., Upfal, E. & Raphael, B. J. in Proc. 14th Internat. Conf. Res. Comput. Mol. Biol. (ed. Berger, B. ) 506-521 (Springer, 2010).
34. Choi, J. H. et al. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 68, 5716-5723 (2008).
35. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
36. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
37. Veeck, J. et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28, e563-e564 (2010).
38. Yap, T. A, et al. Reply to J. Veeck et al. J. Clin. Oncol. 10, e565-e566 (2010).
39. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
40. Nakayama, N. et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116, 2621-2634 (2010).
41. Vaske, C. J. et al. Inference of patient-specific pathway activities from multidimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
42. Schaefer, C. F. et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 37, D674-D679 (2009).
43. Barsotti, A. M. & Prives, C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 28, 4295-4305 (2009).
44. Tone, A. A. et al. Gene expression profiles of luteal phase fallopian tube epithelium fromBRCA mutation carriers resemble high-grade serous carcinoma. Clin. Cancer Res. 14, 4067-4078 (2008).
45. Myatt, S. S. & Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Rev. Cancer 7, 847-859 (2007). (Pubitemid 350006253)
46. Wang, I. C. et al. Deletion of Forkhead Box M1transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis. PLoS ONE 4, e6609 (2009).
47. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
48. Ho, E. S. -C. et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol. Oncol. 80, 189-193 (2001).
49. Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010).
50. Kuo, K. T. et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174, 1597-1601 (2009).
51. Cuatrecasas, M., Villanueva, A., Matias-Guiu, X. & Prat, J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79, 1581-1586 (1997). (Pubitemid 27154791)